VJOncology Podcast

Latest Episodes:

EGFR exon 20 insertions and how to manage patients in the UK Oct 13, 2023

Show notes

EGFR exon 20 insertion mutations represent 5% to 10% of EGFR mutations in patients with non-small cell lung cancer (NSCLC). Despite this form of lung cancer being hard to detect in standard genetic testing, mobocertinib and amivantamab have shown promising results in clinical trials.

In this week’s podcast, join Sanjay Popat, MBBS, FRCP, PhD, The Royal Marsden NHS Foundation Trust, London, UK, Alastair Greystoke, MBChB, MSc, PhD, MRCP, University of Newcastle & Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, UK, Anna Minchom, MD, MRCP, MBBCh, The Royal Marsden NHS Foundation Trust, London, UK, and Riyaz Shah, MBBS, FRCP, PhD, Kent Oncology Centre, Maidstone, UK, as will discuss the identification of EGFR exon 20 insertions and how to manage patients in the UK, based on the recent decisions made by NICE on the use of amivantamab and mobocertinib.

The post EGFR exon 20 insertions and how to manage patients in the UK appeared first on VJOncology.

Updates in immunotherapy for brain tumors Sep 15, 2023

Show notes

Even with aggressive surgical procedures, radiation therapy, and systemic chemotherapy, the outlook for individuals diagnosed with malignant brain tumors remains dismal, and conventional treatments come with notable risks of causing long-term cognitive impairments. There is a pressing and evident demand for the advancement of more efficient therapies that can complement standard approaches for invasive brain cancers while minimizing their harmful side effects. Cancer immunotherapy emerges as a hopeful treatment strategy capable of providing precise tumor-targeted cytotoxicity, offering the potential to eradicate brain tumor cells while preserving the delicate functions of the brain.

In this podcast we hear from Olivia Rongze Lu, PhD, University of California San Francisco, San Francisco, CA, Stephen Joseph Bagley, MD, MSCE, Hospital of the University of Pennsylvania, PA, Anthony Chalmers, MD, University of Glasgow, Glasgow, UK, and Philipp Karschnia, MD, Ludwig-Maximilians-University, Munich, Germany, as they discuss updates in immunotherapy for brain tumors.

The post Updates in immunotherapy for brain tumors appeared first on VJOncology.

Developments in Radiotherapy for GI Cancer Sep 08, 2023

Show notes

For various gastrointestinal (GI) malignancies such as gastric and pancreatic cancer, chemotherapy and surgery remain the standard of care. Numerous trials have been conducted to assess the effectiveness of radiotherapy and chemoradiotherapy in the management of GI cancer.

In this podcast, we hear from Lucjan Wyrwicz, MD, PhD, Maria Sklodowska-Curie National Cancer Research Institute, Warsaw, Poland, Sushma Agrawal, MD, SGPGI, Lucknow, India, Joseph Herman, MD, MSc, MHCM, Northwell Health Cancer Institute, New Hyde Park, NY, as they discuss the current advances in radiotherapy for GI cancer.

The post Developments in Radiotherapy for GI Cancer appeared first on VJOncology.

Latest advances in early-stage breast cancer Aug 25, 2023

Show notes

Over the last decades, systemic therapy for patients with early-stage breast cancer has undergone remarkable enhancements, with the objectives and structures of neoadjuvant clinical trials continuously developing.

In this podcast, we are joined by Sara Tolaney, MD, MPH, Dana-Farber Cancer Institute, Boston, MA, Michael Gnant, MD, FACS, FEBS, Medical University of Vienna, Vienna, Austria, Hope S. Rugo, MD, Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, Justin Balko, PharmD, PhD, Vanderbilt University Medical Center, Nashville, TN, as they discuss advances in early-stage HER2-positive, HR-positive and triple-negative breast cancer.

The post Latest advances in early-stage breast cancer appeared first on VJOncology.

Applications of AI in Oncology Aug 18, 2023

Show notes

Cancer plays a substantial role in worldwide mortality, accounting for approximately 9.3 million deaths each year. Despite considerable strides made over recent decades, the challenge of delivering personalized care persists. In an effort to mitigate this, the integration of artificial intelligence (AI) tools has been suggested across various realms within the field of oncology. The applications of AI in oncology encompass the refinement of cancer research methodologies, the enhancing of clinical protocols, gaining deeper insights into the intricate characteristics of tumors, and more.

In this podcast, we hear from Manisha Palta, MD, Duke University, Durham, NC, Benoit Gallix, MD, PhD, American Hospital of Paris, Neuilly-sur-Seine, France, Andrew J. Armstrong, MD, MSc, Duke Cancer Institute, Durham, NC, David A. Mankoff, MD, PhD, Abramson Cancer Center, Philadelphia, PA, and Young Kwang Chae, MD, MPH, MBA, National Cancer Institute, Bethesda as they discuss current and future applications of AI in oncology.

The post Applications of AI in Oncology appeared first on VJOncology.

Targeted radionuclide therapy in prostate cancer Aug 11, 2023

Show notes

Prostate cancer stands as the most frequently detected malignant condition among men, ranking as the second primary contributor to cancer-linked fatalities in Western society. While localized prostate cancer can be addressed through various efficient treatments, nearly all patients eventually advance to the state of incurable metastatic castration-resistant prostate cancer. Given the substantial toll on both mortality and quality of life due to the disease’s progression, there exists a pressing demand for novel, precisely targeted therapeutic interventions.

Targeted radionuclide therapy is an increasingly favored treatment option for prostate cancer, attributed to its ability to administer a greatly concentrated absorbed dose precisely to the intended tumor site, all the while safeguarding the neighboring healthy tissues.

In this podcast, we hear from Jeremie Calais, MD, MSc, University of California, Los Angeles, CA, Scott Tagawa, MD, MS, FACP, Weill Cornell Medical Center, New York, NY, and Shahneen Sandhu, MBBS, FRACP, Peter MacCallum Cancer Centre, Melbourne, Australia, on some of the latest updates in targeted radionuclide therapy for prostate cancer.

The post Targeted radionuclide therapy in prostate cancer appeared first on VJOncology.

Latest updates in mesothelioma Aug 04, 2023

Show notes

In this latest episode from VJOncology, join us as we explore the latest news in mesothelioma research with three distinguished speakers. Anthony Chalmers, MD, University of Glasgow, Glasgow, UK, Dean Fennell, MBBS, PhD, FRCP, University Hospitals of Leicester NHS Trust, Leicester, UK, and Riyaz Shah, BSc(Hons), MBBS, FRCP, PhD, Kent Oncology Centre, UK. Discover the Phase II SYSTEMS-2 trial’s potential to reshape mesothelioma treatment and revolutionize patient care, unravel the excitement surrounding targeted therapy, particularly the TEAD inhibitor IK-930, showing great promise in disrupting cancer-promoting pathways, and finally learn more about the crucial role of immunotherapy in combating mesothelioma and its potential to offer new avenues for improved patient outcomes.

The post Latest updates in mesothelioma appeared first on VJOncology.

iwCAR-T Session V: Advances in head & neck and CNS cancers Jul 28, 2023

Show notes

The 5th International Workshop on CAR-T (iwCAR-T) took place in Scottsdale, AZ, on 14 – 16 April 2023, and brought together world-leading experts in CAR-T therapy as they discussed the latest in the field. In this podcast series, you will gain an insight into the sessions that took place at this year’s meeting, which covered the latest updates in CAR-T therapy in solid tumors, as well as associated challenges.

In this episode, Kedar Kirtane, MD, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, Rizwan Romee, MD, Dana-Farber Cancer Institute, Boston, MA, and Jong Chul Park, MD, Massachusetts General Hospital, Boston, MA, share their insights on potential therapies for head and neck cancer, focusing on combination treatments and novel therapeutics. Topics discussed include the use of memory-like NK cells in combination with long-acting IL-15 and checkpoint inhibitors for enhanced efficacy, as well as the advantages of NK cell-based therapies over traditional T cell-based CAR treatments, including reduced side effects and increased responsiveness to tumor cells. In addition, the discussion explores strategies to overcome challenges, such as immune suppressive phenotypes and tumor microenvironments.

The post iwCAR-T Session V: Advances in head & neck and CNS cancers appeared first on VJOncology.

Highlights in GI cancer from ESMO WCGIC 2023 Jul 21, 2023

Show notes

The ESMO World Congress on Gastrointestinal Cancer (WCGIC) 2023 brought together world-renowned experts in oncology to present and discuss the latest advances in gastrointestinal cancer. In this podcast, we hear from leading healthcare professionals as they provide an overview of highlights from this year’s meeting. We will be joined by Philip Philip (Wayne State University School of Medicine/Henry Ford Health, Detroit, MI), Shouki Bazarbashi (King Faisal Specialist Hospital and Research Center-Riyadh, Riyadh, Saudi Arabia), and Anna Wagner (University of Lausanne, Lausanne, Switzerland).

We will hear on the feasibility of precision medicine approaches in pancreatic cancer, as well as findings from the INNOVATION trial, which assessed chemotherapy with trastuzumab and pertuzumab in patients HER2-positive gastric cancer. Several colorectal trials will additionally be discussed, including VELO, DEEPER, IMPROVE and AVETRIC, which all assessed the feasibility of panitumumab or cetuximab in the metastatic setting.

The post Highlights in GI cancer from ESMO WCGIC 2023 appeared first on VJOncology.

Updates in immunotherapy for head and neck cancer Jul 14, 2023

Show notes

In this podcast we’ll be covering some of the latest updates in immunotherapy for head and neck cancer. Ezra Cohen, MD, FRCPSC, FASCO, Moores Cancer Center at UC San Diego Health, San Diego, CA, discusses the clinical activity of petosemtamab, a bispecific antibody targeting EGFR and LGR5, in patients with head and neck squamous carcinoma (HNSCC). Nabil Saba, MD, FACP, Winship Cancer Institute of Emory University, Atlanta, GA, presents findings from a Phase II trial (NCT03468218) of pembrolizumab and cabozantinib in patients HNSCC. Ari Rosenberg, MD, University of Chicago, Chicago, IL, describes the trial design of the Phase II DEPEND trial (NCT03944915), which assessed neoadjuvant nivolumab, paclitaxel, and carboplatin followed by response-stratified chemoradiation (CRT) in locoregionally advanced HPV-negative HNSCC. Blessie Elizabeth Nelson, MBBS, DMRT, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the ongoing study investigating the synergy between the potential efficacy of Clostridium novyi with pembrolizumab. Lastly, Heath Devin Skinner, MD, PhD, Hillman Cancer Center, Pittsburgh, PA, shares findings from the Phase II study (NCT03715946), which aimed to investigate treatment de-intensification for resected human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma (OPSCC) by adding nivolumab to a reduced radiation therapy (RT) regimen.

The post Updates in immunotherapy for head and neck cancer appeared first on VJOncology.

Our TOPPODCAST Picks

Follow Us

Stay Connected

Related Podcasts

Links

Stay Connected